Scholarlink

Background <p>Romosozumab/AMG785 (Evenity<sup>®</sup>, Amgen and UCB pharma, RMZ) is a sclerostin-neutralizing antibody that rapidly increases BMD, but very short-term monitoring in clinical routine is limited by specific issues of available ionizing techniques.</p> Aims <p>To assess the effectiveness of the radiation-free Radiofrequency Echographic Multi Spectrometry (REMS) for very short-term monitoring of RMZ in postmenopausal women.</p> Methods <p>Seventy-four postmenopausal women starting RMZ and 52 postmenopausal women not receiving anti-osteoporosis drugs underwent proximal femur REMS scans at baseline and after 6 months, assessing total hip (TH) and femoral neck (FN) BMD. Exploratory analyses were also performed in treatment-naïve patients and in women with ≥ 2 prior fragility fractures.</p> Results <p>After six months of RMZ, BMD significantly increased at both TH (+ 3.7%; 0.718 ± 0.103&#xa0;g/cm<sup>2</sup> vs. 0.698 ± 0.116&#xa0;g/cm<sup>2</sup>; <i>p</i> &lt; 0.01) and FN (+ 4.1%, 0.572 ± 0.092&#xa0;g/cm<sup>2</sup> vs. 0.556 ± 0.105&#xa0;g/cm<sup>2</sup>; <i>p</i> ≤ 0.01). In treatment-naïve patients (<i>n</i> = 33), BMD gains were larger (TH + 4.7%; FN + 4.6%), as also in women with ≥ 2 prior fractures (<i>n</i> = 36), where TH BMD increased by 4.1% and FN BMD by 4.8%. In untreated controls, no significant changes were observed at either TH (-0.8%; <i>p</i> &gt; 0.05) or FN (-0.6%; <i>p</i> &gt; 0.05). Weight and BMI did not change significantly over the considered 6-month interval.</p> Conclusions <p>REMS detected clinically-relevant 6-month increases in femoral BMD during RMZ therapy, while BMD remained stable in untreated controls. These findings, together with anthropometric stability, support the feasibility of REMS for very short-term follow-up in real-world settings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Very short-term monitoring of Romosozumab longitudinal effects in a cohort of postmenopausal women by means of Radiofrequency Echographic Multi-Spectrometry (REMS) technology

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月11日

查看全文
  • Angelo Semeraro,
  • Angela Chialà,
  • Andrea Carafa,
  • Rosalinda Fanizzi,
  • Elisabetta Di Tano,
  • Maria Palmisano,
  • Carmela Santoro,
  • Federica Dibenedetto,
  • Nicola Napoli

摘要

Background

Romosozumab/AMG785 (Evenity®, Amgen and UCB pharma, RMZ) is a sclerostin-neutralizing antibody that rapidly increases BMD, but very short-term monitoring in clinical routine is limited by specific issues of available ionizing techniques.

Aims

To assess the effectiveness of the radiation-free Radiofrequency Echographic Multi Spectrometry (REMS) for very short-term monitoring of RMZ in postmenopausal women.

Methods

Seventy-four postmenopausal women starting RMZ and 52 postmenopausal women not receiving anti-osteoporosis drugs underwent proximal femur REMS scans at baseline and after 6 months, assessing total hip (TH) and femoral neck (FN) BMD. Exploratory analyses were also performed in treatment-naïve patients and in women with ≥ 2 prior fragility fractures.

Results

After six months of RMZ, BMD significantly increased at both TH (+ 3.7%; 0.718 ± 0.103 g/cm2 vs. 0.698 ± 0.116 g/cm2; p < 0.01) and FN (+ 4.1%, 0.572 ± 0.092 g/cm2 vs. 0.556 ± 0.105 g/cm2; p ≤ 0.01). In treatment-naïve patients (n = 33), BMD gains were larger (TH + 4.7%; FN + 4.6%), as also in women with ≥ 2 prior fractures (n = 36), where TH BMD increased by 4.1% and FN BMD by 4.8%. In untreated controls, no significant changes were observed at either TH (-0.8%; p > 0.05) or FN (-0.6%; p > 0.05). Weight and BMI did not change significantly over the considered 6-month interval.

Conclusions

REMS detected clinically-relevant 6-month increases in femoral BMD during RMZ therapy, while BMD remained stable in untreated controls. These findings, together with anthropometric stability, support the feasibility of REMS for very short-term follow-up in real-world settings.